EFG Asset Management North America Corp. Increases Stock Holdings in Krystal Biotech, Inc. $KRYS

EFG Asset Management North America Corp. lifted its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 18.4% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 27,095 shares of the company’s stock after buying an additional 4,217 shares during the quarter. EFG Asset Management North America Corp.’s holdings in Krystal Biotech were worth $4,784,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Edgestream Partners L.P. purchased a new stake in shares of Krystal Biotech in the second quarter valued at about $2,705,000. Voya Investment Management LLC raised its position in shares of Krystal Biotech by 46.7% during the 3rd quarter. Voya Investment Management LLC now owns 93,908 shares of the company’s stock worth $16,578,000 after purchasing an additional 29,915 shares during the last quarter. State of New Jersey Common Pension Fund D lifted its stake in Krystal Biotech by 45.2% in the 2nd quarter. State of New Jersey Common Pension Fund D now owns 15,033 shares of the company’s stock valued at $2,066,000 after buying an additional 4,682 shares in the last quarter. Tempus Wealth Planning LLC acquired a new stake in Krystal Biotech during the 2nd quarter valued at $327,000. Finally, Norges Bank acquired a new stake in Krystal Biotech during the 2nd quarter valued at $38,861,000. 86.29% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

KRYS has been the subject of a number of analyst reports. Zacks Research raised Krystal Biotech from a “hold” rating to a “strong-buy” rating in a report on Wednesday, January 7th. Citigroup boosted their target price on shares of Krystal Biotech from $320.00 to $336.00 and gave the company a “buy” rating in a research note on Monday, January 12th. HC Wainwright reaffirmed a “buy” rating and set a $310.00 price target (up from $240.00) on shares of Krystal Biotech in a research note on Friday, January 9th. Bank of America boosted their price objective on shares of Krystal Biotech from $288.00 to $318.00 and gave the company a “buy” rating in a research report on Thursday, January 22nd. Finally, Guggenheim set a $224.00 target price on shares of Krystal Biotech and gave the stock a “buy” rating in a research report on Friday, October 17th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $271.75.

Krystal Biotech Price Performance

NASDAQ KRYS opened at $278.75 on Tuesday. The company has a market cap of $8.08 billion, a P/E ratio of 41.79 and a beta of 0.46. Krystal Biotech, Inc. has a 12 month low of $122.80 and a 12 month high of $295.98. The company has a 50-day moving average of $245.52 and a 200-day moving average of $193.84.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, November 3rd. The company reported $2.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.12 by $1.54. Krystal Biotech had a net margin of 53.30% and a return on equity of 19.36%. The firm had revenue of $97.80 million during the quarter, compared to the consensus estimate of $93.72 million. As a group, equities research analysts anticipate that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Insider Activity

In other news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $220.16, for a total transaction of $5,504,000.00. Following the completion of the sale, the insider directly owned 1,413,711 shares in the company, valued at $311,242,613.76. This represents a 1.74% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. 13.70% of the stock is owned by corporate insiders.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.